Showing results (251-260 of 366) with videos related to

Sort By:
Pageof 37
JTO Clinical and Research Reports|July 22, 2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 TrialBenjamin J Solomon, Ibiayi Dagogo-Jack, Se-Hoon Lee, et al.
The Lancet. Oncology|March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialDong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trialEnriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJames Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|February 29, 2024
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Lancet (London, England)|August 9, 2025
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trialFabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 12, 2025
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER StudyAntonio Calles, Alejandro Navarro, Bernard Gaston Doger de Speville Uribe, et al.
JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.
Expert Review of Anticancer Therapy|December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.
Pageof 37